Niacin (Vitamin B3) 是一种具有口服活性的水溶性B3维生素 (B3 vitamin),是人类必需的营养物质。Niacin (Vitamin B3) 在能量代谢、细胞信号级联调节基因表达和细胞凋亡 (apoptosis) 中起关键作用,也可用于心血管疾病的研究。
生物活性 | Niacin (Vitamin B3) is an orally active water-solubleB3 vitaminthat is an essential nutrient for humans. Niacin (Vitamin B3) plays a key role in energy metabolism, cell signaling cascades regulating gene expression andapoptosis. Niacin (Vitamin B3) is also used in the study of cardiovascular diseases[1][2]. |
IC50& Target | Microbial Metabolite | Human Endogenous Metabolite |
|
体外研究 (In Vitro) | Niacin (0-900 μM, 42 hours) significantly increases GSH levels and decreases ROS levels, and affects the expression of genes related to apoptosis and lipid metabolism[1]. Niacin (0-40 μM, 24 hours) can inhibit cancer invasive activity at low dose but with no influence on proliferation[2].
RT-PCR[1] Cell Line: | Cumulus cells and oocytes of prepubertal gilts | Concentration: | 600 μM | Incubation Time: | 42 hours | Result: | Up-regulated the relative expression of the anti-apoptotic gene BCL2 and lipid metabolism gene ACACA while down-regulated the pro-apoptotic gene BAX. |
Cell Proliferation Assay[2] Cell Line: | Rat ascites hepatoma cell line of AH109A | Concentration: | 0-40 μM | Incubation Time: | 24 hours | Result: | Had no effect on the proliferation of AH109A cells but suppressed cell invasion from 2.5 μM to 40 μM. |
|
体内研究 (In Vivo) | Niacin (subcutaneous injection, 3-300 mg/kg, once) can induce vasodilation in a dose-dependent manner within minutes in male C57BL/6 mice[3].
Animal Model: | Male C57BL/6 mice[3] | Dosage: | 3-300 mg/kg | Administration: | Subcutaneous injection; once | Result: | Induced vasodilation in a dose-dependent manner. |
|
Clinical Trial | |
分子量 | |
性状 | |
Formula | |
CAS 号 | |
中文名称 | |
结构分类 | - Ketones, Aldehydes, Acids
|
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Powder | -20°C | 3 years | | 4°C | 2 years | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
溶解性数据 | In Vitro: DMSO : 50 mg/mL(406.14 mM;ultrasonic and warming and heat to 60℃) H2O : 10 mg/mL(81.23 mM;Need ultrasonic) 配制储备液 1 mM | 8.1228 mL | 40.6141 mL | 81.2282 mL | 5 mM | 1.6246 mL | 8.1228 mL | 16.2456 mL | 10 mM | 0.8123 mL | 4.0614 mL | 8.1228 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: PBS Solubility: 110 mg/mL (893.51 mM); Clear solution; Need ultrasonic 2. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: 2.08 mg/mL (16.90 mM); Suspended solution; Need ultrasonic
此方案可获得 2.08 mg/mL (16.90 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。 以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 3. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.08 mg/mL (16.90 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (16.90 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 4. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 2.08 mg/mL (16.90 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (16.90 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|